Developer docs
API playgroundTry for free, no card

Search company profiles

Cereius

Full company profile

uuid0003r9x

Namestring
Cereius
Websiteurl
cereius.io
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Cereius is a pre-clinical biotechnology company developing novel therapeutic approaches to treat solid tumor brain metastasis, headquartered in Durham, North Carolina, and founded in 2017.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology therapeutics, brain metastasis treatment, preclinical drug development, cancer research, biotechnology R&D
Industry1 code
PRIMARYHLAKAFAH
Neuro-Oncology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Oncology Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cereius is a pre-clinical stage biotechnology company developing novel therapeutic approaches for the treatment of solid tumour brain metastasis. The company's work is centered on early-stage drug discovery and translational research targeting metastatic disease in the brain. It does not yet have approved or commercially available products.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

Clinical-stage company developing targeted radiopharmaceuticals for CNS cancers, including brain metastases and recurrent glioblastoma. Highly comparable modality and indication focus to Cereius.

TypeDirect peer
Description

Oncology-focused developer of paxalisib and other brain-penetrant therapies for glioblastoma and brain metastases. Closely comparable CNS oncology pipeline and stage.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing IL-2 and IL-4 Superkines for brain tumors and other solid tumors. Comparable brain-cancer focus and pre-clinical-to-early-clinical stage.

TypeDirect peer
Description

Clinical-stage company developing therapies for primary and metastatic brain cancers. Comparable patient population and CNS-oncology positioning.

TypeDirect peer
Description

Late-stage developer of therapeutics for CNS cancers, including glioblastoma and brain metastases. Comparable indication focus at a more advanced clinical stage.

TypeEmerging player
Description

Privately held developer of SurVaxM and other immunotherapies for brain tumors. Comparable brain-cancer immunology approach at a similar private, pre-commercial stage.

TypeDirect peer
Description

Developer of DCVax dendritic-cell immunotherapies, including DCVax-L for brain cancer. Comparable brain-cancer immunotherapy orientation.

TypeBroad incumbent
Description

Commercial-stage company marketing Tumor Treating Fields (Optune) for glioblastoma and other solid tumors. Comparable CNS-oncology focus but at a much later, commercial stage.

9ABM Therapeutics
TypeEmerging player
Description

Clinical-stage oncology company developing small molecules designed to cross the blood-brain barrier for brain tumors and metastases. Comparable CNS-penetrant oncology strategy.

TypeBroad incumbent
Description

Commercial-stage radiopharmaceutical company with growing CNS oncology and brain-metastasis imaging/therapy programs. Comparable modality and indication space at a far larger scale.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cereius

Oncology Therapeuticscereius.io

Cereius is a pre-clinical biotechnology company developing novel therapeutic approaches to treat solid tumor brain metastasis, headquartered in Durham, North Carolina, and founded in 2017.

Cereius firmographics

Firmographics
Name
Cereius
Website
https://cereius.io
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Short description
Cereius is a pre-clinical biotechnology company developing novel therapeutic approaches to treat solid tumor brain metastasis, headquartered in Durham, North Carolina, and founded in 2017.
Ownership category
akta.pro rank

Cereius industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAKAFAH
Neuro-Oncology

Keywords

  • Oncology therapeutics
  • Brain metastasis treatment
  • Preclinical drug development
  • Cancer research
  • Biotechnology R&D

Where Cereius is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

Cereius business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Cereius product offering

Product offering

Core offering

Cereius is a pre-clinical stage biotechnology company developing novel therapeutic approaches for the treatment of solid tumour brain metastasis. The company's work is centered on early-stage drug discovery and translational research targeting metastatic disease in the brain. It does not yet have approved or commercially available products.

Differentiator

Problem solved

Functional benefit

Companies that use Cereius

Customer profile

Ideal customer profiles1 record

Cereius technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cereius competitors and assessment

Company assessment

Direct peers

  • Plus Therapeutics: Clinical-stage company developing targeted radiopharmaceuticals for CNS cancers, including brain metastases and recurrent glioblastoma. Highly comparable modality and indication focus to Cereius.
  • Kazia Therapeutics: Oncology-focused developer of paxalisib and other brain-penetrant therapies for glioblastoma and brain metastases. Closely comparable CNS oncology pipeline and stage.
  • Medicenna Therapeutics: Clinical-stage immuno-oncology company developing IL-2 and IL-4 Superkines for brain tumors and other solid tumors. Comparable brain-cancer focus and pre-clinical-to-early-clinical stage.
  • CNS Pharmaceuticals: Clinical-stage company developing therapies for primary and metastatic brain cancers. Comparable patient population and CNS-oncology positioning.
  • Kintara Therapeutics: Late-stage developer of therapeutics for CNS cancers, including glioblastoma and brain metastases. Comparable indication focus at a more advanced clinical stage.
  • Northwest Biotherapeutics: Developer of DCVax dendritic-cell immunotherapies, including DCVax-L for brain cancer. Comparable brain-cancer immunotherapy orientation.

Emerging players

  • MimiVax: Privately held developer of SurVaxM and other immunotherapies for brain tumors. Comparable brain-cancer immunology approach at a similar private, pre-commercial stage.
  • ABM Therapeutics: Clinical-stage oncology company developing small molecules designed to cross the blood-brain barrier for brain tumors and metastases. Comparable CNS-penetrant oncology strategy.

Broad incumbents

  • Novocure: Commercial-stage company marketing Tumor Treating Fields (Optune) for glioblastoma and other solid tumors. Comparable CNS-oncology focus but at a much later, commercial stage.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with growing CNS oncology and brain-metastasis imaging/therapy programs. Comparable modality and indication space at a far larger scale.

Market position

Customer concentration

Cereius social profiles

Digital presence

Cereius financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cereius leadership team

Management profile

Number of profiles

Profiles3 records

Cereius funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cereius M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cereius

What does Cereius do?

Cereius is a pre-clinical stage biotechnology company developing novel therapeutic approaches for the treatment of solid tumour brain metastasis. The company's work is centered on early-stage drug discovery and translational research targeting metastatic disease in the brain. It does not yet have approved or commercially available products.

When was Cereius founded?

Cereius was founded in 2017. It employs 1 to 10 people.

Where is Cereius based?

Cereius is headquartered in Durham, United States, in the North America region.

Who are Cereius's main competitors?

Direct peers on record are Plus Therapeutics, Kazia Therapeutics, Medicenna Therapeutics, CNS Pharmaceuticals, Kintara Therapeutics and Northwest Biotherapeutics. Emerging players are MimiVax and ABM Therapeutics. Broad incumbents are Novocure and Telix Pharmaceuticals.

Does Cereius have an API?

No public API is recorded for Cereius.

What industry is Cereius in?

Cereius's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAKAFAH, Neuro-Oncology. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals